SynthesisBMC gastroenterology2026
The impact of statin use on colorectal cancer prognosis: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evidence considering the potential protective impact of statins on the mortality rate caused by colorectal cancer (CRC) is controversial. This study aimed to systematically assess the effect of statins on the survival rate of CRC patients.
methodsA comprehensive search was conducted in Scopus, PubMed, and Web of Science to assess the relationship between statin consumption and cancer-specific mortality (CSM), all-cause mortality (ACM), disease-free survival (DFS), and recurrence-free survival (RFS). Subgroup analyses were performed to assess data stratified by country, study design, disease stage, time to use, CRC, and treatment type due to high heterogeneity.
resultsThirty-two studies were included; the data of 24 articles composed the meta-analysis. Statins improved prognosis of CRC, particularly in lower ACM (HR: 0.80; 95% CI: 0.74–0.87) with I²=90%, P-value < 0.01, and lower CSM (HR: 0.74; 95% CI: 0.67–0.82) with I²=88%, P-value < 0.01 when compared to non-users. Both pre- and post-diagnostic statin use were linked to lower ACM and CSM, though high heterogeneity was observed across studies. However, the results for statin use on RFS indicated an HR of 1.01 with 95% CI of 0.94 to 1.09 (I² = 0% and P-value = 0.93). Additionally, for DFS, the HR was 0.93 (95% CI: 0.85–1.01) with I² = 47%, suggesting no meaningful effect of statin use on DFS. No significant publication bias was found.
conclusionStatin use was associated with a reduction in ACM and CSM in CRC patients. However, the variances in RFS and DFS were not statistically significant. However, these findings should be interpreted cautiously due to substantial heterogeneity among some included studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.